Sign in

CIK 0001651308

  • Large accelerated filer

BeOne Medicines Ltd.

Sign in to watch
Ticker
BEIGF
Exchange
Nasdaq, OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
981209416
Phone
+41 616851900
Business address
C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
Former names
BeiGene, Ltd.

Securities

  • ONC American Depositary Shares Nasdaq
  • BEIGF Common stock OTC
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$48,487,541
in 9 filings, $47.8M under 10b5-1 plans

Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Date Insider Transaction Shares Price Value Owned after
2016-02-08 BAKER BROS. ADVISORS LP Director Conversion · Series A-2 Preferred shares −1,912,167 0
2016-02-08 BAKER BROS. ADVISORS LP Director Conversion · Series A-2 Preferred shares −26,292,961 0
2016-02-08 BAKER BROS. ADVISORS LP Director Option exercise · Ordinary stock warrant (right to buy) −238,850 0
2016-02-08 BAKER BROS. ADVISORS LP Director Option exercise · Ordinary stock warrant (right to buy) −2,296,890 0
2016-02-08 BAKER BROS. ADVISORS LP Director Option exercise · Ordinary stock warrant (right to buy) −56,853 0
2016-02-08 OYLER JOHN CEO Conversion +9,398,380 59,780,349
2016-02-08 OYLER JOHN CEO Option exercise · Series A Warrant (Right to Buy) −57,777 0
2016-02-08 OYLER JOHN CEO Option exercise · Series A Preferred Shares +57,777 9,398,380
2016-02-08 OYLER JOHN CEO Conversion · Series A Preferred Shares −9,398,380 0
2016-02-08 Chen Timothy Yung-Cheng Director Grant or award · Share Option (Right to Buy) +460,626 460,626
2016-02-08 Liang Howard CFO & Chief Strategy Officer Purchase +65,000 $1.85 $120K 65,000
2016-02-08 Yuan RuiRong Chief Medical Officer Purchase +130,000 $1.85 $241K 130,000
2016-02-08 CB Biotech Investment Ltd 10% owner Conversion +19,601,138 19,601,138
2016-02-08 CB Biotech Investment Ltd 10% owner Conversion · Series A Preferred Shares −14,814,814 0
2016-02-08 CB Biotech Investment Ltd 10% owner Conversion · Series A-2 Preferred Shares −4,786,324 0

Page 123 of 123 · 2,455 trades